The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28613895 |
66 |
A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose. |
Eli Lilly |
27966948 |
86 |
Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach. |
Pharmaceutical |
28337319 |
28 |
Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization. |
Universit£ |
27914947 |
11 |
Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs). |
University of Florence |
27825552 |
152 |
Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. |
Takeda Pharmaceutical |
27452283 |
241 |
Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays. |
Jadavpur University |
27038494 |
18 |
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis. |
Fudan University |
27039251 |
66 |
Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors. |
Shandong University |
26871660 |
68 |
Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models. |
San Raffaele Scientific Institute |
26653735 |
81 |
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis. |
Pfizer |
26753813 |
22 |
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid. |
University of Minnesota |
26638045 |
58 |
Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors. |
Uit The Arctic University of Norway |
26346367 |
77 |
Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis. |
Nanjing University |
26386821 |
15 |
Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase. |
Shandong University |
26263024 |
47 |
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity. |
Universit£ |
26192023 |
71 |
SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes. |
Florida Atlantic University |
25264600 |
64 |
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. |
Takeda Pharmaceutical |
25921268 |
36 |
New matrix metalloproteinase inhibitors based on¿-fluorinateda-aminocarboxylic anda-aminohydroxamic acids. |
Westf£Lische Wilhelms-Universit£T M£Nster |
25438884 |
11 |
A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging. |
University Medical Center Groningen |
25415648 |
63 |
Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis. |
Eli Lilly |
25265401 |
38 |
Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors. |
Universidad Ceu San Pablo |
25192810 |
66 |
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site. |
Takeda Pharmaceutical |
24813742 |
98 |
Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors. |
Universit£ |
24755524 |
60 |
Design, synthesis and preliminary evaluation ofa-sulfonyl¿-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors. |
Shandong University |
24028490 |
46 |
O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier. |
University of Notre Dame |
23453070 |
42 |
A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors. |
Asahi Kasei Pharma |
23376997 |
53 |
Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation. |
Universit£ |
23375794 |
220 |
Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors. |
Nanjing University of Chinese Medicine |
23353736 |
41 |
Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1). |
Second Military Medical University |
23287054 |
46 |
Sulphonamides: Deserving class as MMP inhibitors? |
Indian Institute of Technology (Bhu) |
23458498 |
24 |
Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography. |
Universit£ |
23246356 |
52 |
MMP inhibition by barbiturate homodimers. |
Trinity College |
17275314 |
701 |
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. |
Pomona College |
21669521 |
44 |
Selective non zinc binding inhibitors of MMP13. |
Astrazeneca |
23134659 |
74 |
Design and synthesis of procollagen C-proteinase inhibitors. |
Fibrogen |
24900417 |
59 |
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis. |
TBA |
22894736 |
99 |
Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment. |
The Hebrew University of Jerusalem |
21780776 |
40 |
Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry. |
Wroclaw University of Technology |
21413800 |
56 |
A one-pot synthesis and biological activity of ageladine A and analogues. |
Macquarie University |
23149299 |
50 |
Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9. |
Universit£ |
22967811 |
62 |
Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold. |
Tianjin Medical University |
22540974 |
67 |
A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation. |
University Hospital M£Nster |
22248361 |
24 |
Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion. |
Trinity College |
22737278 |
44 |
Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors. |
TBA |
22658537 |
76 |
Natural products as a gold mine for selective matrix metalloproteinases inhibitors. |
East China University of Science and Technology |
22175799 |
22 |
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. |
Alantos Pharmaceuticals |
22607877 |
38 |
Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors. |
Shandong University |
19715320 |
87 |
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. |
University of Florida |
19635666 |
119 |
Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety. |
Incyte |
19339187 |
49 |
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II). |
Shandong University |
19329328 |
42 |
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I). |
Shandong University |
19095454 |
63 |
Current perspective of TACE inhibitors: a review. |
The M. S. University of Baroda |
17981034 |
51 |
1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke. |
Johnson & Johnson Pharmaceutical Research and Development |
18053726 |
364 |
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. |
Johnson & Johnson Pharmaceutical Research & Development |
17980583 |
46 |
Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs). |
Johnson & Johnson Pharmaceutical Research and Development |
18086526 |
85 |
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification. |
Johnson & Johnson Pharmaceutical Research and Development |
18257543 |
16 |
Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. |
The Hebrew University of Jerusalem |
18251495 |
69 |
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. |
Pfizer |
18061445 |
103 |
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Research and Development |
18029173 |
316 |
Synthesis and evaluation of novel heterocyclic MMP inhibitors. |
North Dakota State University |
17956082 |
86 |
Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. |
University Hospital of The Westf£Lische Wilhelms-Universit£T M£Nster |
17127067 |
21 |
Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. |
Instituto Superior T£Cnico |
17276072 |
95 |
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. |
Universit£ |
15857146 |
30 |
C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging. |
University Hospital of The Westf£Lische Wilhelms-Universit£T |
15713379 |
40 |
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. |
Universit£ |
15582436 |
7 |
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity. |
Sejong University |
15139760 |
110 |
Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. |
The Hebrew University of Jerusalem |
12930146 |
170 |
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors. |
Institut De Recherches Servier |
12773042 |
195 |
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. |
Wyeth Research |
11472217 |
157 |
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. |
Dupont Pharmaceuticals |
11472202 |
143 |
Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. |
TBA |
10669559 |
180 |
Protease inhibitors: current status and future prospects. |
University of Queensland |
10649971 |
180 |
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. |
Parke-Davis Pharmaceutical Research |
10579818 |
162 |
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. |
Procter and Gamble Pharmaceuticals |
9888835 |
42 |
Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. |
Procter and Gamble Pharmaceuticals |
1322986 |
13 |
Inhibition of collagenase by aranciamycin and aranciamycin derivatives. |
Technical University of Denmark |
14980648 |
16 |
New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors. |
Universit£ |
15177439 |
96 |
Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. |
Pfizer |
12824028 |
75 |
Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. |
Pfizer |
11327577 |
86 |
Heterocycle-based MMP inhibitors with P2' substituents. |
Procter and Gamble Pharmaceuticals |
11591510 |
57 |
alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1. |
Pfizer |
11378378 |
34 |
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors. |
Celltech-Chiroscience |
11133099 |
43 |
Synthesis and activity of selective MMP inhibitors with an aryl backbone. |
Pharmacia |
10450979 |
4 |
Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents. |
University of Cambridge |
10397503 |
40 |
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. |
Universit£ |
22386984 |
67 |
In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors. |
Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl) |
22175825 |
19 |
Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
Pfizer |
22118188 |
50 |
A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography. |
University Hospital M£Nster |
22153941 |
140 |
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2. |
Astrazeneca |
22017539 |
75 |
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. |
Boehringer Ingelheim Pharmaceuticals |
22017477 |
35 |
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases. |
Instituto Superior T£Cnico |
22153340 |
37 |
Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). |
Pfizer |
22082667 |
67 |
Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors. |
Microbiotix |
22088955 |
33 |
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization. |
Universit£ |
21937229 |
82 |
Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13. |
Novartis Institutes For Biomedical Research |
21925881 |
60 |
Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy. |
Johnson & Johnson Pharmaceutical Research & Development |
21866961 |
28 |
Selective water-soluble gelatinase inhibitor prodrugs. |
University of Notre Dame |
21911297 |
40 |
Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors. |
Shandong University |
21802307 |
64 |
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine. |
Shandong University |
21764590 |
98 |
N-substituted homopiperazine barbiturates as gelatinase inhibitors. |
Trinity College |
20726512 |
282 |
Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. |
Pfizer |
21514700 |
56 |
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. |
Universit£ |
21536437 |
219 |
Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis. |
Astrazeneca |
20638281 |
56 |
Structure and activity relationships of tartrate-based TACE inhibitors. |
Merck Research Laboratories |
21507637 |
102 |
MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres. |
Pfizer |
21493063 |
67 |
MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides. |
Pfizer |
21458257 |
87 |
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors. |
Merck Research Laboratories |
21300546 |
129 |
The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis. |
Astrazeneca |
21189019 |
22 |
Identifying chelators for metalloprotein inhibitors using a fragment-based approach. |
University of California |
24900296 |
38 |
Sulfonate-Containing Thiiranes as Selective Gelatinase Inhibitors |
TBA |
20970895 |
4 |
2-Azetidinone--a new profile of various pharmacological activities. |
Barkatullah University |
21106451 |
39 |
Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases. |
Merck Research Laboratories |
20637634 |
48 |
Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione. |
Shandong University |
20529685 |
70 |
MMP-13 selective isonipecotamide alpha-sulfone hydroxamates. |
Pfizer |
20529684 |
112 |
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates. |
Pfizer |
20180536 |
128 |
Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models. |
Universit£ |
20172725 |
49 |
Discovery and SAR of hydantoin TACE inhibitors. |
Merck Research Laboratories |
20053563 |
10 |
Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida. |
Wonkwang University Sanbon Medical Center |
20022498 |
71 |
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors. |
Schering-Plough Research Institute |
19969464 |
56 |
Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors. |
Shandong University |
20097082 |
20 |
Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I). |
Shandong University |
20005097 |
58 |
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. |
Pfizer |
19948404 |
1 |
Synthesis and anticancer activities of ageladine A and structural analogs. |
Beckman Research Institute At City of Hope |
19782572 |
62 |
Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. |
Shandong University |
19703773 |
63 |
The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. |
Gsk Medicines Research Centre |
19775099 |
184 |
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. |
Universit£ |
19454370 |
52 |
Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors. |
Shandong University |
19625186 |
59 |
3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding. |
Wyeth Research |
19524436 |
27 |
Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. |
University of Shizuoka and Global Coe Program |
19725580 |
93 |
Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma. |
Wyeth Research |
19606871 |
124 |
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. |
Universit£ |
18835710 |
69 |
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket. |
Schering-Plough Research Institute |
| 2 |
Synthesis of conformationally constrained potential inhibitors of mammalian metalloproteinases |
TBA |
| 97 |
Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket |
TBA |
| 30 |
Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics |
TBA |
| 30 |
Orally active inhibitors of stromelysin-1 (MMP-3) |
TBA |
| 60 |
Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptides |
TBA |
| 49 |
Phosphinic acid inhibitors of matrix metalloproteinases |
TBA |
| 18 |
Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1' |
TBA |
| 66 |
Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalanines |
TBA |
| 40 |
Novel indolactam-based inhibitors of matrix metalloproteinases |
TBA |
| 60 |
Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivatives |
TBA |
| 76 |
Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivatives |
TBA |
19457660 |
90 |
Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition. |
Incyte |
19410464 |
71 |
Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors. |
Wyeth Research |
19329309 |
49 |
Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors. |
Wyeth Research |
19261472 |
16 |
Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. |
University of California |
19053764 |
101 |
Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. |
Instituto Superior TéCnico |
18996018 |
42 |
Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN). |
Shandong University |
18945617 |
50 |
Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents. |
Pfizer |
18790648 |
317 |
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. |
University of Athens |
18782669 |
90 |
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. |
Université |
18718763 |
50 |
Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. |
Shandong University |
18571419 |
24 |
Novel aminopeptidase N inhibitors derived from 1,3,4-thiadiazole scaffold. |
Shandong University |
18467109 |
21 |
Design, synthesis, and QSAR studies of novel lysine derives as amino-peptidase N/CD13 inhibitors. |
Shandong University |
18440232 |
38 |
Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. |
Shandong University |
18362041 |
59 |
Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors. |
Shandong University |
17719700 |
39 |
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors. |
Università |
17623656 |
34 |
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. |
Pfizer |
18083558 |
112 |
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents. |
Johnson & Johnson Pharmaceutical Research and Development |
18068976 |
132 |
Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations. |
Incyte |
18036818 |
157 |
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis. |
Incyte |
18029177 |
57 |
A novel series of highly selective inhibitors of MMP-3. |
Pfizer |
17936631 |
25 |
Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. |
Yonsei University |
17591762 |
102 |
Potent and selective nonpeptidic inhibitors of procollagen C-proteinase. |
Pfizer |
17583333 |
4 |
Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12. |
Università |
17576061 |
132 |
Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
17531482 |
67 |
Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors. |
Wyeth Research |
17512742 |
32 |
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies. |
Université |
17433673 |
44 |
Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors. |
Shandong University |
17428670 |
1 |
Inhibitory effect of obovatal on the migration and invasion of HT1080 cells via the inhibition of MMP-2. |
Korea Research Institute of Bioscience and Biotechnology |
17368021 |
55 |
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Pharmaceutical Research Institute |
17276676 |
112 |
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
17267227 |
12 |
Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases. |
Clermont Auvergne University |
17256836 |
84 |
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer. |
Incyte |
17188863 |
107 |
Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Pharmaceutical Research Institute |
17088065 |
106 |
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs. |
Università |
17064892 |
123 |
Identification of potent and selective TACE inhibitors via the S1 pocket. |
Wyeth Research |
17027261 |
153 |
Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Pharmaceutical Research Institute |
16723229 |
108 |
Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors. |
Wyeth Research |
16632358 |
68 |
Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. |
Johnson & Johnson Pharmaceutical Research and Development |
16516466 |
175 |
Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
16473009 |
23 |
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
16420030 |
38 |
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. |
Chinese Academy of Sciences |
16392792 |
29 |
Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. |
Aventis Pharma Deutschland |
16289878 |
35 |
Conversion of potent MMP inhibitors into selective TACE inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
16242329 |
12 |
N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8. |
Università |
16153831 |
87 |
Synthesis and SAR of highly selective MMP-13 inhibitors. |
Wyeth Research |
16005220 |
52 |
Identification of potent and selective MMP-13 inhibitors. |
Wyeth Research |
16002291 |
24 |
Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. |
Pfizer |
15953722 |
56 |
Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13. |
Pfizer |
15908214 |
95 |
Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
15837315 |
13 |
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. |
Università |
15780611 |
74 |
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. |
Pfizer |
15686921 |
55 |
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). |
Pharmaceutical Research Institute |
15357971 |
228 |
Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
15341955 |
52 |
Synthesis and evaluation of novel oxazoline MMP inhibitors. |
North Dakota State University |
15324896 |
71 |
3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase. |
Pfizer |
15163188 |
12 |
A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations. |
University of California San Francisco |
15125955 |
84 |
Reverse hydroxamate-based selective TACE inhibitors. |
Kaken Pharmaceutical |
14711305 |
26 |
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. |
University of Athens |
14684295 |
109 |
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. |
Chinese Academy of Sciences |
14643313 |
132 |
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
14643312 |
39 |
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
14611841 |
10 |
MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3. |
Umr/Cnrs 6013 |
12877590 |
28 |
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. |
Pfizer |
12877587 |
6 |
Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty. |
National Cardiovascular Center Research Institute |
12798337 |
6 |
Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. |
Indiana University School of Medicine |
12781190 |
113 |
Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Pharmaceutical Research Institute |
12729664 |
14 |
Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives. |
Université |
12723945 |
167 |
Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
12408705 |
73 |
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. |
Bristol-Myers Squibb |
11754593 |
148 |
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. |
Abbott Laboratories |
11738583 |
45 |
Potent P1' biphenylmethyl substituted aggrecanase inhibitors. |
Bristol-Myers Squibb Pharma |
11677124 |
67 |
Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme. |
Abbott Laboratories |
11585440 |
76 |
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release. |
Dupont Pharmaceuticals |
11585439 |
44 |
Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. |
Dupont Pharmaceuticals |
11563922 |
147 |
Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. |
UniversitäT Bielefeld |
11551755 |
18 |
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor. |
British Biotech Pharmaceuticals |
11543676 |
45 |
Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors. |
Université |
11543675 |
104 |
N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets. |
Université |
11454461 |
111 |
The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold. |
Procter and Gamble Pharmaceuticals |
11428927 |
117 |
A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities. |
The Royal Danish School of Pharmacy |
11412980 |
48 |
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770. |
Abbott Laboratories |
11412979 |
67 |
Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. |
Abbott Laboratories |
11354379 |
37 |
Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors. |
Pfizer |
11327602 |
58 |
Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. |
Roche Research Center |
11297453 |
173 |
Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines. |
Procter and Gamble Pharmaceuticals |
32491863 |
11 |
Inhibiting Matrix Metalloproteinase-2 Activation by Perturbing Protein-Protein Interactions Using a Cyclic Peptide. |
University of California |
11266157 |
12 |
Chemoenzymatic synthesis of functionalized cyclohexylglycines and alpha-methylcyclohexylglycines via Kazmaier-Claisen rearrangement. |
University of Florida |
31874775 |
176 |
Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors. |
"A. Moro" University of Bari |
11229774 |
40 |
Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). |
Pfizer |
11229773 |
73 |
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality. |
Pfizer |
11212095 |
65 |
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors. |
Institut De Recherches Servier |
11150165 |
228 |
Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. |
Procter and Gamble Pharmaceuticals |
30594678 |
22 |
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview. |
Jadavpur University |
32379447 |
44 |
Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF |
Westf£Lische Wilhelms-Universit£T M£Nster |
10937713 |
186 |
Solid-phase synthesis of an arylsulfone hydroxamate library. |
Rhone-Poulenc Rorer |
10882354 |
19 |
Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold. |
Pfizer |
27194201 |
164 |
Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors. |
Eli Lilly |
10794702 |
340 |
Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties. |
Università |
10639284 |
119 |
Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold. |
University of Florida |
31415980 |
68 |
Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors. |
Shandong University |
31330449 |
9 |
Role of sulphur-heterocycles in medicinal chemistry: An update. |
Maharaja Ranjit Singh Punjab Technical University |
31251594 |
57 |
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions. |
Monash University |
10522712 |
109 |
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors. |
British Biotech Pharmaceuticals |
10522699 |
37 |
Design, combinatorial chemical synthesis and in vitro characterization of novel urea based gelatinase inhibitors. |
University of Wisconsin-Madison |
10411481 |
144 |
Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. |
Cea |
30954331 |
54 |
Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies. |
University of Hamburg |
30926311 |
16 |
Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds. |
University of Florence |
10346925 |
40 |
Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. |
Shionogi |
10052961 |
24 |
Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template. |
RhôNe-Poulenc Rorer |
10021913 |
42 |
Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket. |
Pfizer |
30537832 |
7 |
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases. |
Monash University |
9873712 |
109 |
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors. |
Abbott Laboratories |
30522899 |
28 |
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP). |
Universit£ |
9873491 |
56 |
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors. |
Abbott Laboratories |
9873367 |
39 |
Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. |
Abbott Laboratories |
9599226 |
25 |
Macrocyclic amino carboxylates as selective MMP-8 inhibitors. |
Dupont Pharmaceuticals |
9548812 |
67 |
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. |
Kanebo |
9484512 |
130 |
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
Shionogi |
9457244 |
189 |
Matrix metalloproteinase inhibitors: a structure-activity study. |
Glycomed |
30342958 |
56 |
Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy. |
Nanjing Agricultural University |
9191969 |
31 |
Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives. |
Institut De Recherche Servier |
9083493 |
95 |
Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. |
Merck Research Laboratories |
30846252 |
23 |
Recent developments in the synthesis and applications of phosphinic peptide analogs. |
Wroclaw University of Technology |
26810711 |
30 |
Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography. |
Westf£Lische Wilhelms-Universit£T |
8277511 |
57 |
Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides. |
Merck Research Laboratories |
24247003 |
25 |
Sulphonamide 1,4-dithia-7-azaspiro[4,4]nonane derivatives as gelatinase A inhibitors. |
Shandong University |
8064799 |
16 |
Cyclic peptides with a phosphinic bond as potent inhibitors of a zinc bacterial collagenase. |
University of Athens |
23899323 |
87 |
Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation. |
University Hospital M£Nster |
23688254 |
31 |
Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9. |
Eth Zurich |
20056543 |
2 |
Anti-invasive and anti-angiogenic activities of naturally occurring dibenzodiazepine BU-4664L and its derivatives. |
Toyama Prefectural University |
12502345 |
1 |
Sodium 1-(12-hydroxy)octadecanyl sulfate, an MMP2 inhibitor, isolated from a tunicate of the family Polyclinidae. |
The University of Tokyo |
18474428 |
25 |
Design of antiangiogenic hypoxic cell radiosensitizers: 2-nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety. |
The University of Tokushima |
12014967 |
25 |
Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. |
Preclinical Research Novartis Pharma |
30093347 |
10 |
Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity. |
Weifang Medical University |
30212201 |
17 |
Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing. |
University of Notre Dame |
29524731 |
76 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease. |
Banaras Hindu University |
29921475 |
37 |
Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration. |
Guangxi Normal University |
29630364 |
63 |
Design of Aminopeptidase N Inhibitors as Anti-cancer Agents. |
Jadavpur University |
29727184 |
56 |
Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies. |
Universit£ |
28818461 |
67 |
Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis. |
Nestl� |
30249495 |
241 |
Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study. |
Graz University of Technology |
30034605 |
15 |
In Search of Selectivity in Inhibition of ADAM10. |
University of Notre Dame |
29028530 |
48 |
A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line. |
Jadavpur University |
28191850 |
164 |
Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
University of California San Diego |
28850227 |
85 |
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry. |
St. John'S University |
28558971 |
38 |
Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors. |
Merck |
28408220 |
55 |
First insight into structure-activity relationships of selective meprin? inhibitors. |
Fraunhofer Institute For Cell Therapy and Immunology Izi |
28653849 |
67 |
Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors. |
Scripps Florida |
21524149 |
13 |
Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands. |
Suven Life Sciences |
16206837 |
9 |
Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors. |
University of Karachi |
9353361 |
3 |
[3H]RY 80: A high-affinity, selective ligand for gamma-aminobutyric acidA receptors containing alpha-5 subunits. |
National Institute of Diabetes and Digestive and Kidney Diseases |
8524985 |
69 |
D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. |
Case Western Reserve University |
7680751 |
48 |
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. |
National Institute of Neurological Disorders and Stroke |
7518496 |
9 |
Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase. |
Syntex Discovery Research |
7515823 |
54 |
Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family. |
Novo Nordisk |
7509389 |
8 |
Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide. |
Fujisawa Pharmaceutical |
18355729 |
12 |
Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin. |
University of Dundee |
19695884 |
156 |
Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides. |
Vernalis (R&D) |
19462975 |
18 |
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. |
Chemical Genomics Centre of The Max Planck Society |
17034127 |
45 |
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. |
University of Newcastle Upon Tyne |
19345579 |
14 |
Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles. |
Wyeth Research |
19267461 |
53 |
Novel tricyclic inhibitors of IkappaB kinase. |
Bristol-Myers Squibb |